CMN Weekly (1 July 2022) - Your Weekly CRISPR...
Jul. 1, 2022
Relevant Interviews, Disease and Trial Updates and Stock-Markets News posted by CRISPR Medicine News.
Check also Companies to Follow in 2022 and CMN Markets for the latest stock and market trends.
Always stay updated with the free CMN Newsletter.
TCR2 Therapeutics
Main focus: Next-generation iPSC-derived cell therapies
Company stage: Clinical
Diseases (gene editing): Solid tumours, haematological cancers
Genome editing tool: CRISPR
Funding stage: Public (NASDAQ:TCRR)
Location: Cambridge, MA, USA
Website: https://www.tcr2.com/
Pipeline: https://www.tcr2.com/our-pipeline/
Gene editing partnerships: Arbor Biotechnologies
TCR2 Therapeutics is developing next-generation cellular therapies to treat cancer. The company's technology is based on TCR Fusion Construct (TRuC) T cells that are engineered to recognise tumour cells. The company's engagement in the gene-editing space comes through its collaboration with Arbor Biotechnologies, giving TCR2 access to CRISPR-based gene-editing systems for the development of allogeneic cell therapies.
